MCID: PNC025
MIFTS: 58

Panic Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 54 12 52 41 42 14 69
Panic Disorder 1 29 69
Panic Disorder Syndrome 1 13
Panic Anxiety Syndrome 12
Panic 52

Characteristics:

OMIM:

54
Inheritance:
? autosomal dominant form


Classifications:



External Ids:

OMIM 54 167870
Disease Ontology 12 DOID:594
MeSH 42 D016584
NCIt 47 C34890
ICD10 33 F41.0
SNOMED-CT via HPO 65 48694002
UMLS 69 C0030319

Summaries for Panic Disorder

OMIM : 54
The DSM-IV (American Psychiatric Association, 1994) defines panic disorder as the spontaneous, unexpected occurrence of panic attacks followed by persistent concern, worry, and anxiety about having additional panic attacks. Panic attacks are defined as a discrete period of intense fear or discomfort in which at least 4 of 13 symptom criteria are met that develop abruptly and reach a peak within 10 minutes. Some of these criteria include cardiac palpitations, sweating, feelings of choking, fear of losing control, and fear of dying. Panic disorder is divided into panic disorder with or without accompanying agoraphobia. However, agoraphobia can also occur without panic disorder, and panic attacks can occur in the absence of panic disorder. Comorbidity with depressive and addictive disorders is frequent. Barlow et al. (1994) and Smoller and Tsuang (1998) noted that because the diagnostic criteria remain purely clinical, the nosology of anxiety disorders, such as panic disorder, is controversial and evolving. Therefore, it is difficult to do genetic studies because of the difficulty in delineating overlapping phenotypes within the broader context of anxiety disorders. For example, there may be overlap of panic with specific phobias, variable expressivity of panic and anxiety or depression, or phenocopies within a family. The terms 'anxiety neurosis' and 'phobic neurosis' were used in the past (before the DSM-III in 1980) to encompass all of these disorders. Smoller and Tsuang (1998) suggested that dimensional personality traits, such as shyness, behavioral inhibition, and neuroticism (see 607834), could be used to define an anxiety phenotype. Schumacher et al. (2011) provided a review of the genetics of panic disorder. They noted that there is high (80%) comorbidity with other psychiatric disorders, including agoraphobia, mood disorders, substance abuse, and other anxiety disorders. Associated personality traits include anxiety sensitivity, behavioral inhibition, neuroticism, and harm avoidance. Women are more susceptible to development of the disorder, which has an average age of onset at 23.6 years. (167870)

MalaCards based summary : Panic Disorder, also known as panic disorder 1, is related to personality disorder and schizophrenia, and has symptoms including anxiety An important gene associated with Panic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Paroxetine and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and cortex, and related phenotypes are Decreased viability and behavior/neurological

MedlinePlus : 41 panic disorder is a type of anxiety disorder. it causes panic attacks, which are sudden feelings of terror when there is no real danger. you may feel as if you are losing control. you may also have physical symptoms, such as fast heartbeat chest or stomach pain breathing difficulty weakness or dizziness sweating feeling hot or a cold chill tingly or numb hands panic attacks can happen anytime, anywhere, and without warning. you may live in fear of another attack and may avoid places where you have had an attack. for some people, fear takes over their lives and they cannot leave their homes. panic disorder is more common in women than men. it usually starts when people are young adults. sometimes it starts when a person is under a lot of stress. most people get better with treatment. therapy can show you how to recognize and change your thinking patterns before they lead to panic. medicines can also help. nih: national institute of mental health

Disease Ontology : 12 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

Wikipedia : 72 Panic disorder is an anxiety disorder characterized by recurrent unexpected panic attacks. Panic attacks... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 3 Panic Disorder 2

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
id Related Disease Score Top Affiliating Genes
1 personality disorder 27.9 CCK COMT CRH HTR1A HTR2A MAOA
2 schizophrenia 24.6 ADORA2A CCK CCKAR COMT HTR1A HTR2A
3 panic disorder 3 12.1
4 panic disorder 2 12.0
5 anxiety disorder 11.3
6 agoraphobia 10.9
7 ring chromosome 14 syndrome 10.7 COMT MAOA
8 paranoid personality disorder 10.6 HTR1A HTR2A
9 polyneuropathy 10.6 HTR1A HTR2A
10 hodgkin's granuloma 10.6 HTR1A HTR2A
11 gastrointestinal adenoma 10.6 CCK TSPO
12 tongue disease 10.6 COMT MAOA SLC6A4
13 tinea pedis 10.5 HTR1A MAOA SLC6A4
14 neurogenic bladder 10.5 HTR2A MAOA SLC6A4
15 colon mucinous adenocarcinoma 10.5 COMT MAOA SLC6A4
16 pyromania 10.5 HTR2A MAOA SLC6A4
17 anosognosia 10.5 COMT HTR1A SLC6A4
18 conjunctival pigmentation 10.5 CRH MAOA SLC6A4
19 conjunctival degeneration 10.5 HTR1A HTR2A SLC6A4
20 pompholyx 10.5 HTR1A HTR2A SLC6A4
21 bladder flat intraepithelial lesion 10.4 HTR1A HTR2A SLC6A4
22 generalized anxiety disorder 10.4
23 teebi kaurah syndrome 10.4 COMT HTR2A
24 adult mesenchymal chondrosarcoma 10.3 POMC SLC6A4
25 social phobia 10.3
26 abnormal pupillary function 10.3 HTR1A HTR3A
27 obsessive-compulsive disorder 10.3
28 intermittent squint 10.2 CRH POMC
29 heroin dependence 10.2 MAOA POMC SLC6A4
30 primary angle-closure glaucoma 10.2 COMT HTR1A HTR2A SLC6A4
31 splenic abscess 10.2 HTR2A SLC6A4
32 renal pelvis carcinoma 10.2 CRH POMC
33 tuberculum sellae meningioma 10.2 CCK CCKAR CRH
34 actinobacillosis 10.1 CRH POMC
35 sweat gland cancer 10.1 CCK HTR3A SLC6A4
36 anodontia 10.1 HTR1A HTR3A SLC6A4
37 uterus intravascular leiomyomatosis 10.1 COMT HTR1A MAOA PTK7 SLC6A4
38 ulcerative blepharitis 10.1 CRH POMC
39 alexithymia 10.1
40 hallucinogen dependence 10.1 CRH POMC SLC6A4
41 hypodermyasis 10.1 CRH POMC
42 hypochondriasis 10.1
43 separation anxiety disorder 10.1
44 perinatal necrotizing enterocolitis 10.0 CCK COMT POMC SLC6A4
45 autoimmune disease of central nervous system 10.0 CRH POMC TSPO
46 transsexualism 10.0 HTR1A HTR3A TSPO
47 hyperthyroxinemia 10.0 HTR2A SLC6A4
48 ornithosis 10.0 CCK HTR3A MAOA SLC6A4
49 bipolar disorder 10.0
50 chitty hall webb syndrome 10.0 COMT TPH1

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

Symptoms via clinical synopsis from OMIM:

54

Neuro:
panic disorder (anxiety neurosis)


Clinical features from OMIM:

167870

Human phenotypes related to Panic Disorder:

32
id Description HPO Frequency HPO Source Accession
1 anxiety 32 HP:0000739

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.43 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.43 HTR1A HTR3A SLC6A4
3 Increased transferrin (TF) endocytosis GR00363-A 9.36 ADORA2A CCKAR CCKBR CRH HTR1A HTR2A

MGI Mouse Phenotypes related to Panic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ADORA2A CCK CCKAR CCKBR COMT CRH
2 cardiovascular system MP:0005385 10.21 COMT HTR1A MAOA POMC PTK7 SLC6A2
3 homeostasis/metabolism MP:0005376 10.2 ADORA2A CCK CCKAR CCKBR COMT CRH
4 growth/size/body region MP:0005378 10.15 ADORA2A CCKAR CCKBR CRH HTR3A POMC
5 endocrine/exocrine gland MP:0005379 10.1 CCK CCKAR CCKBR COMT CRH HTR2A
6 nervous system MP:0003631 10 CCKAR CCKBR COMT CRH HTR1A HTR3A
7 integument MP:0010771 9.91 CCKBR CRH HTR3A POMC SLC6A2 SLC6A4
8 renal/urinary system MP:0005367 9.5 CCKAR CCKBR COMT CRH HTR3A POMC
9 respiratory system MP:0005388 9.17 ADORA2A CCKAR COMT CRH PTK7 TPH1

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2 61869-08-7 43815
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
4
Citalopram Approved Phase 4,Phase 1 59729-33-8 2771
5
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1 79617-96-2 68617
8
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 28981-97-7 2118
9
Clonazepam Approved, Illicit Phase 4,Phase 2,Phase 3 1622-61-3 2802
10
Clozapine Approved Phase 4 5786-21-0 2818
11
Vortioxetine Approved Phase 4 508233-74-7 9966051
12
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Ziprasidone Approved Phase 4 146939-27-7 60854
15
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
19 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
20 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
24
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
25 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Anticonvulsants Phase 4,Phase 2,Phase 3
28 Antimanic Agents Phase 4
29 Antipsychotic Agents Phase 4,Phase 3,Phase 2
30 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
31 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Quetiapine Fumarate Phase 4 111974-72-2
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 1,Early Phase 1
35 Antiparkinson Agents Phase 4,Phase 1
36 Autonomic Agents Phase 4,Phase 1,Early Phase 1
37 Cholinergic Agents Phase 4,Phase 1,Early Phase 1
38 Cholinergic Antagonists Phase 4,Phase 1
39 Muscarinic Antagonists Phase 4,Phase 1
40 Parasympatholytics Phase 4,Phase 1
41 Analgesics Phase 4
42 Dopamine Agents Phase 4,Phase 3,Phase 2
43 Duloxetine Hydrochloride Phase 4
44 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
45 Anti-Anxiety Agents Phase 4,Phase 2,Phase 1
46 GABA Modulators Phase 4,Phase 2,Phase 3,Phase 1
47 Hypnotics and Sedatives Phase 4,Phase 2,Phase 1
48 Serotonin Antagonists Phase 4,Phase 3,Phase 2
49 Serotonin 5-HT1 Receptor Agonists Phase 4
50 Serotonin 5-HT3 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 218)

id Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
4 A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients Completed NCT00619892 Phase 4 quetiapine XR;placebo
5 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
6 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
7 Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder Completed NCT00767754 Phase 4 Paxil CR
8 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
9 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
10 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
11 Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
12 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
13 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
14 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravamâ„¢ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
16 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
17 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
18 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
19 The Effects of Treatment With Sertraline for Noncardiac Chest Pain Completed NCT01114100 Phase 4 sertraline;placebo
20 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
21 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
22 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
23 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Non Cardiac Chest Pain and Benign Palpitations Completed NCT00623454 Phase 4
26 Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder Completed NCT00391430 Phase 4 Sertraline
27 Ketamine Infusion for Adolescent Depression and Anxiety Recruiting NCT02579928 Phase 4 Ketamine;Midazolam
28 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
29 A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
30 A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
31 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
32 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
33 Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
34 Psychodynamic Therapy for Treating Panic Disorder Completed NCT00128388 Phase 2, Phase 3
35 Therapies for Treatment-Resistant Panic Disorder Symptoms Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
36 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
37 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
38 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
39 Study Evaluating Venlafaxine ER in Patients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
40 Study Evaluating Venlafaxine ER in Adults With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
41 Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks Completed NCT00279617 Phase 3 levetiracetam
42 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
43 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
44 Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders Completed NCT00102427 Phase 2, Phase 3
45 Telephone-Based Care Management Program for Individuals With Anxiety Disorders Completed NCT00158327 Phase 3
46 Online Treatments for Mood and Anxiety Disorders in Primary Care Completed NCT01482806 Phase 2, Phase 3
47 Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder Completed NCT00277654 Phase 3 Risperidone
48 Fluoxetine for Anxious Children Completed NCT00000381 Phase 3 Fluoxetine
49 Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine Completed NCT01527786 Phase 3 Desvenlafaxine
50 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Genetic tests related to Panic Disorder:

id Genetic test Affiliating Genes
1 Panic Disorder 1 29

Anatomical Context for Panic Disorder

MalaCards organs/tissues related to Panic Disorder:

39
Heart, Brain, Cortex, Amygdala, Testes, Prefrontal Cortex, Cingulate Cortex

Publications for Panic Disorder

Articles related to Panic Disorder:

(show top 50) (show all 1225)
id Title Authors Year
1
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
2
Distinct phasic and sustained brain responses and connectivity of amygdala and bed nucleus of the stria terminalis during threat anticipation in panic disorder. ( 28485259 )
2017
3
The implementation of guided Internet-based cognitive behaviour therapy for panic disorder in a routine-care setting: effectiveness and implementation efforts. ( 28714775 )
2017
4
Quality of Life in Patients with Coronary Artery Disease and Panic Disorder: A Comparative Study. ( 28042398 )
2017
5
Sudden gains in exposure-focused cognitive-behavioral group therapy for panic disorder. ( 28493541 )
2017
6
Does patient reluctance towards exposure and psychologists' attitudes about evidence based practice influence treatment recommendations for panic disorder? An experimental investigation. ( 28325630 )
2017
7
Panic Disorder Comorbidity with Medical Conditions and Treatment Implications. ( 28375724 )
2017
8
Reduced Cortical Thickness in the Temporal Pole, Insula, and Pars Triangularis in Patients with Panic Disorder. ( 28792148 )
2017
9
Basic Self-Disturbances beyond Schizophrenia: Discrepancies and Affinities in Panic Disorder - An Empirical Clinical Study. ( 28259879 )
2017
10
Combined Oral Contraceptive Pill Initiation in a Patient With Major Depressive Disorder, Premenstrual Dysphoric Disorder, Social Anxiety, Panic Disorder, and Histrionic Personality Disorder. ( 28638292 )
2017
11
Short-term efficacy of psychological and psychopharmacological interventions for panic disorder appears not to be different. ( 28673930 )
2017
12
Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms. ( 28712090 )
2017
13
Decision-making in panic disorder. Preliminary report. ( 28953790 )
2017
14
No significant difference in long-term remission between psychological therapies and antidepressants in panic disorder. ( 28701335 )
2017
15
How high level of anxiety in Panic Disorder can interfere in working memory? A computer simulation and electrophysiological investigation. ( 28918162 )
2017
16
Perceived criticism predicts outcome of psychotherapy for panic disorder: Replication and extension. ( 28045286 )
2017
17
Red Blood Cell and Platelet Indices: A Potential Biomarker for Panic Disorder. ( 28479785 )
2017
18
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
19
Impact of childhood trauma on course of panic disorder: contribution of clinical and personality characteristics. ( 28369890 )
2017
20
Association between personality traits and Escitalopram treatment efficacy in panic disorder. ( 28472591 )
2017
21
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
22
Cardiorespiratory concerns shape brain responses during automatic panic-related scene processing in patients with panic disorder. ( 28949287 )
2017
23
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
24
Both anxiety and joint laxity determine the olfactory features in panic disorder. ( 28923431 )
2017
25
Treating Panic Disorder Hypnotically. ( 28891770 )
2017
26
Collaborative care for panic disorder, generalised anxiety disorder and social phobia in general practice: study protocol for three cluster-randomised, superiority trials. ( 28814317 )
2017
27
Mental health service use, depression, panic disorder and life events among Swedish young adults in 2000 and 2010: a repeated cross-sectional population study in Stockholm County, Sweden. ( 28367775 )
2017
28
Panic disorder and cardiovascular diseases: an overview. ( 28893114 )
2017
29
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
30
Natriuretic Peptides in Anxiety and Panic Disorder. ( 28061968 )
2017
31
Misinterpretation of the Borg's Rating of Perceived Exertion Scale by patients with panic disorder during ergospirometry challenge. ( 28761695 )
2017
32
Improvement in adult anxious and avoidant attachment during cognitive behavioral therapy for panic disorder. ( 28826378 )
2017
33
Mean Platelet Volume and Platelet Distribution Width Level in Patients with Panic Disorder. ( 28479788 )
2017
34
The indirect effect of panic disorder on smoking cognitions via difficulties in emotion regulation. ( 28395248 )
2017
35
Anxiety sensitivity as a predictor of broad dimensions of psychopathology after cognitive behavioral therapy for panic disorder. ( 28761346 )
2017
36
Contribution of Group Therapeutic Factors to the Outcome of Cognitive-Behavioral Therapy for Patients with Panic Disorder. ( 28359425 )
2017
37
Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. ( 28068460 )
2017
38
Commonalities and differences in the neural substrates of threat predictability in panic disorder and specific phobia. ( 28331799 )
2017
39
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
40
Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial. ( 28868042 )
2017
41
The development and validation of static and adaptive screeners to measure the severity of panic disorder, social anxiety disorder, and obsessive compulsive disorder. ( 28370638 )
2017
42
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
43
Personality Traits in Panic Disorder Patients With and Without Comorbidities. ( 28926359 )
2017
44
Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. ( 28903165 )
2017
45
Genetic Polymorphism of 1019C/G (rs6295) Promoter of Serotonin 1A Receptor and Catechol-O-Methyltransferase in Panic Disorder. ( 28096880 )
2017
46
Functional neuroanatomy in panic disorder: Status quo of the research. ( 28401046 )
2017
47
Modeling the development of panic disorder with interoceptive conditioning. ( 27887860 )
2017
48
Acid-sensing T cell death associated gene-8 receptor expression in panic disorder. ( 28736033 )
2017
49
Translational approach to the pathophysiology of panic disorder: Focus on serotonin and endogenous opioids. ( 28073587 )
2017
50
Cardiac sarcoidosis resembling panic disorder: a case report. ( 28086847 )
2017

Variations for Panic Disorder

Expression for Panic Disorder

Search GEO for disease gene expression data for Panic Disorder.

Pathways for Panic Disorder

Pathways related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 ADORA2A CCK CCKAR CCKBR CRH HTR1A
2 12.37 COMT HTR1A POMC TPH1 TPH2
3
Show member pathways
12.05 ADORA2A CCKAR CCKBR HTR2A
5 11.91 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
6 11.73 ADORA2A CCKBR HTR2A
7 11.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
8
Show member pathways
11.29 ADORA2A MAOA SLC6A2 SLC6A4 TPH2
9
Show member pathways
11.01 COMT MAOA SLC6A4
10
Show member pathways
10.89 COMT MAOA TPH1
11 10.68 COMT MAOA
12
Show member pathways
10.67 COMT MAOA
13 10.62 CCK CCKBR
14 10.61 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
15 10.34 CRH POMC

GO Terms for Panic Disorder

Cellular components related to Panic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.67 ADORA2A CCK COMT HTR2A
2 neuron projection GO:0043005 9.62 SLC6A2 SLC6A4 TPH1 TPH2
3 integral component of plasma membrane GO:0005887 9.56 ADORA2A CCKAR CCKBR HTR1A HTR2A PTK7
4 neuronal cell body GO:0043025 9.55 ADORA2A CCK CRH HTR2A HTR3A
5 axon GO:0030424 9.02 ADORA2A CCK COMT HTR2A HTR3A
6 integral component of membrane GO:0016021 10.03 ADORA2A CCKAR CCKBR COMT HTR1A HTR2A

Biological processes related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 CCK CCKBR CRH HTR1A HTR2A
2 signal transduction GO:0007165 9.96 ADORA2A CCK CCKAR CCKBR CRH HTR1A
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.81 CCKAR CCKBR HTR2A
4 circadian rhythm GO:0007623 9.77 SLC6A4 TPH1 TPH2
5 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.71 CCKAR CCKBR HTR2A
6 adrenal gland development GO:0030325 9.63 CRH TSPO
7 synaptic transmission, dopaminergic GO:0001963 9.62 ADORA2A CRH
8 vasoconstriction GO:0042310 9.62 HTR1A SLC6A4
9 sensory perception GO:0007600 9.61 ADORA2A CCKBR
10 behavior GO:0007610 9.61 HTR1A HTR2A
11 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
12 catecholamine metabolic process GO:0006584 9.58 COMT MAOA
13 positive regulation of mitochondrial depolarization GO:0051901 9.57 CCK TSPO
14 regulation of behavior GO:0050795 9.56 HTR1A HTR2A
15 monoamine transport GO:0015844 9.55 SLC6A2 SLC6A4
16 positive regulation of glutamate secretion GO:0014049 9.52 ADORA2A CCK
17 aromatic amino acid family metabolic process GO:0009072 9.51 TPH1 TPH2
18 response to drug GO:0042493 9.5 ADORA2A COMT CRH HTR2A SLC6A2 SLC6A4
19 dopamine catabolic process GO:0042420 9.49 COMT MAOA
20 dopamine uptake involved in synaptic transmission GO:0051583 9.48 SLC6A2 SLC6A4
21 indolalkylamine biosynthetic process GO:0046219 9.46 TPH1 TPH2
22 serotonin receptor signaling pathway GO:0007210 9.43 HTR1A HTR2A
23 serotonin biosynthetic process GO:0042427 9.4 TPH1 TPH2
24 regulation of serotonin secretion GO:0014062 9.37 CRH HTR1A
25 regulation of hormone secretion GO:0046883 9.33 CCKAR HTR1A HTR2A
26 cholecystokinin signaling pathway GO:0038188 9.32 CCKAR CCKBR
27 response to pain GO:0048265 8.92 COMT CRH SLC6A2 TSPO

Molecular functions related to Panic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.8 ADORA2A CCKAR CCKBR HTR1A HTR2A
2 hormone activity GO:0005179 9.63 CCK CRH POMC
3 G-protein coupled serotonin receptor activity GO:0004993 9.48 HTR1A HTR2A
4 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A2 SLC6A4
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TPH2
6 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A2 SLC6A4
7 neuropeptide hormone activity GO:0005184 9.26 CCK CRH
8 tryptophan 5-monooxygenase activity GO:0004510 9.16 TPH1 TPH2
9 cholecystokinin receptor activity GO:0004951 8.96 CCKAR CCKBR
10 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR3A

Sources for Panic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....